Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses
- 30 November 2003
- journal article
- clinical trial
- Published by Elsevier in Respiratory Medicine
- Vol. 97, S10-S19
- https://doi.org/10.1016/j.rmed.2003.10.004
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available dataAnnals of Allergy, Asthma & Immunology, 2002
- Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 μ g day−1) versus HFA-fluticasone propionate (1000 μ g day−1) in patients with asthmaRespiratory Medicine, 2001
- Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthmaRespiratory Medicine, 2000
- Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthmaRespiratory Medicine, 2000
- Les détresses respiratoires dans les services d'accueil et d'urgences pédiatriques Epidemiologie et critères d'évaluationArchives de Pédiatrie, 2000
- Letters to the EditorRespiratory Medicine, 2000
- Therapeutic Equivalence of a Novel HFA134a-Containing Metered-Dose Inhaler and the Conventional CFC Inhaler (Berodual®) for the Delivery of a Fixed Combination of Fenoterol/ Ipratropium BromideRespiration, 1997
- CFCs, their Replacements, and the Ozone LayerJournal of Aerosol Medicine, 1995
- CFCs and inhalersThe Lancet, 1994
- The Normal Range of Diurnal Changes in Peak Expiratory Flow Rates: Relationship to Symptoms and Respiratory DiseaseAmerican Review of Respiratory Disease, 1991